Form 4: Definium Therapeutics Officer Sells Shares for Tax Withholding

Definium Therapeutics Chief Commercial Officer Matthew T. Wiley sold 2,867 common shares to cover tax withholding obligations under a Rule 10b5-1 plan.

Summary

• Matthew T. Wiley, Chief Commercial Officer of Definium Therapeutics, Inc., reported a transaction on June 25, 2026.
• Wiley sold 2,867 shares of common stock.
• The sale was to satisfy withholding tax obligations related to the settlement of vested restricted stock units.
• This transaction was executed under a Rule 10b5-1 plan adopted on May 29, 2025.
• The sale price was $45.03 per share.
• Following this transaction, Wiley beneficially owns 174,633 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as the transaction is a routine tax-related sale under a pre-established plan and does not necessarily reflect a negative view of the company's prospects by the executive.

Negatives

• A company executive sold a portion of their holdings, although this was for tax withholding purposes.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates a pre-arranged trading strategy, often employed by executives to diversify holdings or manage tax liabilities without triggering insider trading concerns.

Stakeholder Impact

• Shareholders: The sale is by an executive for tax purposes and is executed under a pre-arranged plan, so it is unlikely to have a significant negative impact on the share price. The remaining beneficial ownership by the executive is substantial.

Key Dates

Keywords

Form 4, SEC Filing, Definium Therapeutics, Insider Trading, Stock Sale, Tax Withholding, Rule 10b5-1, Restricted Stock Units, Matthew T. Wiley